highlights of the quarter

1 Extension of our multiple sclerosis (MS) partnership with pharmaceutical giant
Merck Serono.

2 Release of new data on our Vascular Disrupting
Agent (VDA), BNC105, at major US cancer
research conferences (AACR and ASCO) as well
as publication of BNC105 research in Molecular
Cancer Therapeutics, a prestigious, peer reviewed
journal of the American Association
for Cancer Research.

3 Completion of the second Phase I clinical
trial of anti-anxiety and anti-depression
drug candidate BNC210.